Voronoi Signs New Targeted Therapy R&D Technology Licensing Agreement with Subsidiary

[Asia Economy Reporter Lee Jung-yoon] Voronoi announced on the 29th that it has signed a technology licensing agreement with its subsidiary Voronoi Bio for the research and development of new targeted therapies.

The contract involves the technology licensing agreement for isoxazolidine derivative compounds and two other new drug candidate substances, as well as the acquisition of exclusive implementation rights. The contract period lasts until the expiration of the patent term, and the contract amount was not disclosed due to confidentiality provisions in the contract.

This content was produced with the assistance of AI translation services.